OncoMatch/Clinical Trials/NCT06647901

Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

Is NCT06647901 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ICG (Indocyanine Green) for giant cell tumor of bone.

Phase 1/2RecruitingTang XiaodongNCT06647901Data as of May 2026

Treatment: ICG (Indocyanine Green) — ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.

Check if I qualify

Extracted eligibility criteria

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: RANKL inhibitor (denosumab)

Denosumab ... not used before surgery.

Cannot have received: diphosphonate (diphosphonates)

diphosphonates are not used before surgery.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify